Smo Clinical Research (India) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 03-01-2025
- Paid Up Capital ₹ 0.32 M
as on 03-01-2025
- Company Age 17 Year, 8 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 148.79%
(FY 2023)
- Profit 111.94%
(FY 2023)
- Ebitda 267.23%
(FY 2023)
- Net Worth 7.98%
(FY 2023)
- Total Assets 24.19%
(FY 2023)
About Smo Clinical Research (India)
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.32 M, as per Ministry of Corporate Affairs (MCA) records.
Ramanjaneya Katta, Jakkampudi Sravani, and Rakshith Ramanjaneya serve as directors at the Company.
- CIN/LLPIN
U73100KA2007PTC042650
- Company No.
042650
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 Apr 2007
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Bangalore
Industry
Company Details
- Location
Bangaluru, Karnataka, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Smo Clinical Research (India)?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramanjaneya Katta  | Managing Director | 30-Apr-2007 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Jakkampudi Sravani | Director | 30-Apr-2007 | Current |
| Rakshith Ramanjaneya | Director | 01-Mar-2024 | Current |
Financial Performance of Smo Clinical Research (India).
Smo Clinical Research (India) Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 148.79% increase. The company also saw a substantial improvement in profitability, with a 111.94% increase in profit. The company's net worth moved up by a moderate rise of 7.98%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Smo Clinical Research (India)?
In 2023, Smo Clinical Research (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Indya Clinical Research Private LimitedActive 17 years 8 monthsRamanjaneya Katta, Jakkampudi Sravani and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Smo Clinical Research (India)?
Unlock and access historical data on people associated with Smo Clinical Research (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Smo Clinical Research (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Smo Clinical Research (India)'s trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
